LGR5 recombinant protein is an important tool for cancer stem cell research and targeted drug development.

Author: Senior Product Manager of UA Views：10

LGR5, as a key receptor of the Wnt signaling pathway and a marker of cancer stem cells in multiple tumors, plays an important role in the initiation, progression, metastasis, and drug resistance of colorectal cancer, liver cancer, breast cancer, glioblastoma, and other tumors. Structural characterization, antibody screening, receptor interaction, and functional validation centered on LGR5 recombinant proteins have become important support for the development of LGR5-targeted antibodies, ADCs, bispecific antibodies, CAR-T, and other therapeutics.

Recent Advances
Product Information

Recent Advances

LGR5 Recombinant Protein Is an Important Tool for Cancer Stem Cell Research and Targeted Drug Development

Summary: As a key receptor of the Wnt signaling pathway and a marker of cancer stem cells in multiple tumor types, LGR5 plays an important role in the initiation, progression, metastasis, and drug resistance of colorectal cancer, liver cancer, breast cancer, glioblastoma, and other tumors. Structural characterization, antibody screening, receptor interaction studies, and functional validation based on LGR5 recombinant protein have become important support for the development of LGR5-targeted antibodies, ADCs, bispecific antibodies, and CAR-T therapies.

I. LGR5 Is a G Protein-Coupled Receptor Rich in Leucine-Rich Repeats.

LGR5, also known as GPR49 or GPR67, is a member of the class A rhodopsin-like GPCR family. The human LGR5 gene is located in the 12q22-23 region, and its protein consists of 907 amino acids, including 17 extracellular leucine-rich repeats, N-terminal and C-terminal cysteine-rich flanking structures, multiple glycosylation sites, and 7 highly conserved transmembrane helical domains. This structural feature enables LGR5 to participate simultaneously in ligand recognition, receptor complex formation, and downstream signal transduction.

II. LGR5 Enhances Wnt/β-catenin Signaling Through Its Function as an R-spondin Receptor.

LGR5 is a high-affinity receptor for R-spondin proteins and can cooperate with the Wnt receptor Frizzled and LRP5/6 to enhance Wnt/β-catenin signaling. Its mechanism mainly involves the LGR5/R-spondin complex binding to and internalizing the transmembrane E3 ligases RNF43 and ZNRF3, thereby reducing ubiquitination-mediated degradation of Wnt receptors, increasing the abundance of Wnt receptors on the cell surface, and amplifying Wnt signal output. In intestinal stem cell homeostasis, LGR5-positive cells are considered a stem cell population with self-renewal and multilineage differentiation potential, and Wnt and R-spondin signaling together maintain the balance between their proliferation and differentiation.

III. LGR5 Is Highly Expressed in Multiple Tumors and Is Associated With Cancer Stem Cell Properties.

LGR5 shows limited expression in normal tissues, mainly distributed in intestinal crypts, hair follicles, the reproductive system, and other sites; however, it is often abnormally highly expressed in various tumor tissues. As a cancer stem cell marker, LGR5 has been reported in colorectal cancer, liver cancer, gastric cancer, breast cancer, ovarian cancer, glioblastoma, basal cell carcinoma, and many other tumors. In colorectal cancer, LGR5-positive tumor cells have stronger clonogenic, tumor-initiating, and metastatic potential; in liver cancer, LGR5 is also associated with metabolic stress adaptation, enhanced glycolysis, and chemotherapy resistance. These characteristics make LGR5 an important target in research on tumor recurrence, metastasis, and treatment resistance.

IV. LGR5 Signaling Has Dual Features of Tumor Promotion and Complex Regulation.

Most functional studies show that LGR5 can promote tumor cell proliferation, migration, invasion, epithelial-mesenchymal transition, and angiogenesis by activating the Wnt/β-catenin pathway. In vitro studies also indicate that inhibiting LGR5 can reduce the proliferation and colony-forming ability of colon cancer cells and enhance sensitivity to some chemotherapies, whereas LGR5 overexpression may promote tumor growth and drug resistance. On the other hand, however, LGR5 may also participate in cell adhesion, maintenance of membrane-localized β-catenin, and invasion suppression under specific contexts, and some studies suggest that LGR5 loss may enhance the invasiveness or xenograft tumorigenicity of certain tumor cells. Therefore, the function of LGR5 needs to be understood comprehensively in the context of tumor type, microenvironment, Wnt signaling status, and receptor interaction networks.

V. LGR5 Recombinant Protein Is a Key Reagent for Antibody Screening and Receptor Interaction Research.

LGR5 is a multi-pass transmembrane GPCR protein, and its native conformation, glycosylation modifications, and extracellular domain integrity directly affect antibody binding and functional evaluation. LGR5 recombinant protein can be used for antibody preparation, antibody affinity testing, flow cytometry binding validation, SPR/BLI molecular interaction analysis, receptor-ligand binding studies, and the establishment of LGR5-positive cell detection systems. For full-length or extracellular domain recombinant proteins, selecting an expression system that better preserves native epitopes and glycosylation characteristics helps improve the reliability of antibody screening and drug target validation.

VI. LGR5 Recombinant Protein Supports the Development of Targeted Drugs Such as ADCs, Bispecific Antibodies, and CAR-T Therapies.

At present, LGR5-targeted drug development mainly covers antibody-drug conjugates, bispecific antibodies, and CAR-T cell therapies. Among them, the EGFR/LGR5 bispecific antibody Petosemtamab has entered multiple phase III clinical studies, with indications including head and neck squamous cell carcinoma and colorectal cancer. In terms of CAR-T therapy, LGR5-targeted cell therapy products such as CNA3103 are also in early-stage clinical research. In these development paths, LGR5 recombinant protein can be used for target binding activity evaluation, candidate antibody screening, bispecific antibody pairing validation, CAR recognition epitope confirmation, positive cell monitoring, and establishment of pharmacodynamic biomarker methods, providing upstream raw material support for preclinical research and regulatory submissions.

Conclusion

In response to LGR5 target research and recombinant protein application needs, UniAI provides LGR5/GPR49 His Tag Protein, Human. This product can be used for LGR5 antibody screening and characterization, receptor binding activity evaluation, establishment of LGR5-positive cell detection systems, mechanistic research related to the Wnt/R-spondin pathway, and target validation in the development of ADCs, bispecific antibodies, CAR-T therapies, and other drugs. By providing stable and reliable recombinant protein tools, UniAI can provide technical support for cancer stem cell marker research and LGR5-targeted drug development.

LGR5 recombinant protein is becoming an important bridge connecting cancer stem cell biology and targeted therapy development. As the roles of LGR5 in tumor initiation, metastasis, drug resistance, and immune microenvironment regulation continue to be elucidated, high-quality recombinant proteins will play an even more important role in antibody drug screening, receptor interaction analysis, functional validation, and preclinical evaluation.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Nanjing Univ is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UNIV Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next